Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Short term Debt (2019 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Short term Debt for 6 consecutive years, with $149000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Short term Debt rose 192.16% to $149000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $149000.0, a 192.16% increase, with the full-year FY2024 number at $65000.0, changed N/A from a year prior.
  • Short term Debt was $149000.0 for Q3 2025 at NovaBay Pharmaceuticals, up from $111000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $1.3 million in Q3 2023 to a low of $51000.0 in Q3 2024.
  • A 4-year average of $464800.0 and a median of $130000.0 in 2025 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: crashed 95.98% in 2024, then surged 192.16% in 2025.
  • NovaBay Pharmaceuticals' Short term Debt stood at $105000.0 in 2021, then surged by 1109.52% to $1.3 million in 2023, then tumbled by 94.88% to $65000.0 in 2024, then soared by 129.23% to $149000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Short term Debt are $149000.0 (Q3 2025), $111000.0 (Q2 2025), and $84000.0 (Q1 2025).